Small-Vessel Vasculitis Studies
If you are interested in any of our research studies, please contact our research group at 215-614-4417 or email us at rheumatologyresearch@uphs.upenn.edu.
|
Study Name
|
Medication Involved
|
Disease Studied
|
Currently Enrolling
|
| Abatacept (CTLA4-Ig) for the Treatment of Relapsing, Non Severe, GPA (ABROGATE) |
YES |
GPA |
NO |
| The Assessment of Prednisone in Remission Trial (TAPIR) |
YES |
GPA |
NO |
| Benralizumab in eosinophilic granulomatosis with polyangiitis (EGPA) (MANDARA) |
YES |
EGPA |
NO |
| 5506: The EGPA Registry |
NO |
EGPA |
YES |
| Nasal Microbiome in ANCA Associated Vasculitis and Relapsing Polychondritis (NMB) |
NO |
EGPA & RP |
YES |
| Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis (LoDoNaVasc) |
YES |
GPA, MPA, EGPA, GCA, Takayasu arteritis, PAN |
YES |
| One-Time DNA Study for Vasculitis (OTD) |
NO |
GPA, MPA, EGPA, GCA, Takayasu arteritis, PAN |
YES |
| Clinical Transcriptomics in Systemic Vasculitis (CUTIS) |
NO |
GPA, MPA, EGPA, PAN, IgAV, cryoglobulinemic, drug-induced, isolated cutaneous small vessel vasculitis, urticarial |
YES |
| Tissue Repository Collection Protocol |
NO |
GPA, MPA, EGPA, GCA, Takayasu's arteritis, PAN, cutaneous vasculitis |
YES |
| A Randomized Multicenter Study for Isolated Skin Vasculitis (ARAMIS) |
YES |
Cutaneous small/medium vessel vasculitis, cPAN, or IgA vasculitis |
YES |
| Depemokimab compared with mepolizumab for relapsing or refractory EGPA on standard of care therapy (OCEAN) |
YES |
EGPA |
YES |
| Obinutuzumab versus Rituximab in PR3-Patients with ANCA-Associated Vasculitis (PRRR) |
YES |
GPA/MPA |
YES |
